Previous 10 | Next 10 |
Summary Today, we circle back on Rhythm Therapeutics for the first time in over a year and a half. The company continues to advance its main asset Imcivree across multiple indications and recently addressed its near-term financing needs. The stock is up some 125% in 2022 on th...
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathw...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
-- Book developed in collaboration with the Bardet-Biedl Syndrome Foundation -- -- BBS Global Day on Sept. 24 coordinated by BBS International -- BOSTON, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical comp...
BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocort...
-- CARE-BBS multi-country survey of 242 caregivers of individuals with Bardet-Biedl syndrome (BBS) provides extensive details on impact of hyperphagia and obesity -- -- New analyses of Phase 3 data showed setmelanotide achieved substantial weight loss benefit in adolescent and ped...
Rhythm Pharmaceuticals ( NASDAQ: RYTM ) shares are down 11.7% after-hours after the firm prices its public offering of 4.8M shares of its common stock at a public offering price of $26.00/share. All of the shares are being offered by Rhythm. Underwriters are grante...
Rhythm Pharmaceuticals ( NASDAQ: RYTM ) on Wednesday announced a proposed public offering of $100M of its shares. Shares of RYTM, which ended 24.3% higher on Wednesday, dropped ~12% after hours. RYTM intends to grant underwriters a 30-day option to buy up to an...
Rhythm Pharmaceuticals ( NASDAQ: RYTM ) on Tuesday said the European Commission had expanded the marketing approval for its Imcivree drug to include the treatment of obesity and control of hunger associated with Bardet-Biedl syndrome (BBS). BBS is a genetic condition t...
-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement with HealthCare Royalty -- -- Health Canada grants Priority Review sta...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...